Search Results - "Schwartz, Jules I."

Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX-2 Versus COX-1 in Healthy Subjects by Schwartz, Jules I., Dallob, Aimee L., Larson, Patrick J., Laterza, Omar F., Miller, Jutta, Royalty, Jane, Snyder, Karen M., Chappell, Derek L., Hilliard, Deborah A., Flynn, Mary E., Cavanaugh Jr, Paul F., Wagner, John A.

“…We determined cyclo‐oxygenase‐1 and cyclo‐oxygenase‐2 inhibition in healthy middle‐aged subjects (41–65 years) randomly assigned to four 7‐day treatment…”
Get full text

The Disposition and Metabolism of Rofecoxib, a Potent and Selective Cyclooxygenase-2 Inhibitor, in Human Subjects by HALPIN, Rita A, PORRAS, Arturo G, SCHWARTZ, Jules I, LASSETER, Kenneth C, VYAS, Kamlesh P, BAILLIE, Thomas A, GEER, Leslie A, DAVIS, Margaret R, CUI, Donghui, DOSS, George A, WOOLF, Eric, MUSSON, Donald, MATTHEWS, Catherine, MAZENKO, Ralph

“…The disposition and metabolism of rofecoxib, a selective cyclooxygenase-2 inhibitor, were examined in healthy human subjects and in cholecystectomy patients…”
Get full text

Inhibition of Exercise-Induced Bronchoconstriction by MK-571, a Potent Leukotriene D4–Receptor Antagonist by Manning, Patrick J, Watson, Richard M, Margolskee, Dorothy J, Williams, Vanessa C, Schwartz, Jules I, O'Byrne, Paul M

“…EXERCISE is a common stimulus of bronchoconstriction in subjects with asthma. 1 Exercise-induced bronchoconstriction may be caused by alterations in the…”
Get full text

An Evaluation of the Dose-Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe by Bachmann, Kenneth, White, Donald, Jauregui, Luis, Schwartz, Jules I., Agrawal, Nancy G. B., Mazenko, Ralph, Larson, Patrick J., Porras, Arturo G.

“…This study was undertaken to determine whether rofecoxib can interfere with CYP1A2 activity in humans using theophylline as a probe substrate. Single oral…”
Get full text

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers by van Hecken, Anne, Schwartz, Jules I., Depré, Marleen, de Lepeleire, Inge, Dallob, Aimee, Tanaka, Wesley, Wynants, Kathleen, Buntinx, Agnes, Arnout, Jef, Wong, Peggy H., Ebel, David L., Gertz, Barry J., de Schepper, Paul J.

“…Steady‐state inhibitory activity of rofecoxib (Vioxx™) on COX‐2 versus COX‐1 was compared with that of commonly used nonsteroidal anti‐inflammatory drugs…”
Get full text

Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin by Schwartz, Jules I., Musser, Bret J., Tanaka, Wesley K., Taggart, William V., Mehta, Anish, Gottesdiener, Keith M., Greenberg, Howard E.

“…This double‐blind, randomized crossover study assessed the effect of acetaminophen (1000 mg every 8 hours) versus indomethacin (50 mg every 8 hours) versus…”
Get full text

The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin by Dallob, Aimee, Luo, Wen-Lin, Luk, Julie Mabalot, Ratcliffe, Lisa, Johnson-Levonas, Amy O., Schwartz, Jules I., Dishy, Victor, Kraft, Walter K., De Hoon, Jan N., Van Hecken, Anne, De Lepeleire, Inge, Radziszewski, Waldemar, Wagner, John A., Lai, Eseng

“…Laropiprant (LRPT) is being developed in combination with Merck's extended-release niacin (ERN) formulation for the treatment of dyslipidemia. LRPT, an…”
Get full text

Examination of the Effect of Increasing Doses of Etoricoxib on Oral Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis by Schwartz, Jules I., Agrawal, Nancy G. B., Wong, P. H., Miller, Jutta, Bachmann, Kenneth, Marbury, Thomas, Hoelscher, David, Cavanaugh Jr, Paul F., Gottesdiener, Keith

“…The authors designed 2 randomized controlled studies to examine the effects of etoricoxib 60 to 120 mg daily on methotrexate pharmacokinetics in 50 rheumatoid…”
Get full text

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects by Lai, Eseng, Schwartz, Jules I., Dallob, Aimee, Jumes, Patricia, Liu, Fang, Kraft, Walter K., Royalty, Jane, Chodakewitz, Jeffrey A., Mccrary Sisk, Christine, Radziszewski, Waldemar, Wagner, John A.

“…Laropiprant (LRPT) has been shown to reduce flushing symptoms induced by niacin and has been combined with niacin for treatment of dyslipidemia. LRPT, a potent…”
Get full text

Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib by Schwartz, Jules I., Agrawal, Nancy G. B., Wehling, Martin, Musser, Bret J., Gumbs, Carol P., Michiels, Nicole, De Smet, Marina, Wagner, John A.

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Digoxin is a well‐recognized inotropic agent with a narrow therapeutic index. • Nonsteroidal anti‐inflammatory…”
Get full text

Effects of Etoricoxib and Comparator Nonsteroidal Anti-Inflammatory Drugs on Urinary Sodium Excretion, Blood Pressure, and Other Renal Function Indicators in Elderly Subjects Consuming a Controlled Sodium Diet by Schwartz, Jule I., Thach, Chau, Lasseter, Kennet C., Miller, Jutta, Hreniuk, David, Hilliard, Debora A., Snyder, Kare M., Gertz, Barr J., Gottesdiener, Keit M.

“…This multicenter, double‐blind, randomized, placebo‐controlled, parallel‐group study assessed renal function during dosing with etoricoxib 90 mg daily,…”
Get full text

Single- and Multiple-Dose Pharmacokinetics of Etoricoxib, a Selective Inhibitor of Cyclooxygenase-2, in Man by Agrawal, Nancy G. B., Porras, Arturo G., Matthews, Catherine Z., Rose, Mark J., Woolf, Eric J., Musser, Bret J., Dynder, Andrea L., Mazina, Katherine E., Lasseter, Kenneth C., Hunt, Thomas L., Schwartz, Jules I., McCrea, Jacqueline B., Gottesdiener, Keith M.

“…The single‐ and multiple‐dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase‐2, were examined in two clinical studies. Single‐dose…”
Get full text

Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin by Schwartz, Jules I, Liu, Fang, Stroh, Mark, Gipson, Adrianna, Johnson-Levonas, Amy O, Lasseter, Kenneth C, Lai, Eseng, Wagner, John A

“…Laropiprant (LRPT), a prostaglandin D2 receptor 1 antagonist shown to reduce niacin-induced flushing symptoms, is being developed in combination with niacin…”
Get full text

Lack of Effect of Antacids on Single-Dose Pharmacokinetics of Etoricoxib by Schwartz, Jules I., Agrawal, Nancy G. B., Kher, Uma A., DeSmet, Marina, Cavanaugh Jr, Paul F., Guillaume, Michel, Ebel, David L., Merschman, Shelia A., Wagner, John A.

Get full text

Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women by Schwartz, Jules I, Liu, Fang, Wang, Ying-Hong, Pramanik, Barnali, Johnson-Levonas, Amy O, Gutierrez, Maria J, Lai, Eseng, Wagner, John A

“…Laropiprant is a prostaglandin D2 receptor 1 antagonist that is being developed in combination with niacin for the treatment of dyslipidemia. This randomized…”
Get full text

The Effect of Etoricoxib on the Pharmacodynamics and Pharmacokinetics of Warfarin by Schwartz, Jules I., Agrawal, Nancy G. B., Hartford, Alan H., Cote, Josee, Hunt, Thomas L., Verbesselt, Rene, Eckols, Dane R., Gottesdiener, Keith M.

“…The effects of etoricoxib on pharmacodynamic and pharmacokinetic parameters of warfarin were determined in healthy men and women. Subjects titrated with…”
Get full text

Influence of Taranabant, an Orally Active, Highly Selective, Potent Cannabinoid-1 Receptor (CB1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Plasma Pharmacokinetics by Schwartz, Jules I., Dunbar, Stephanie, Yuan, Jinyu, Li, Susie, Miller, Deborah L., Rosko, Kim, Johnson-Levonas, Amy O., Lasseter, Kenneth C., Wagner, John A.

“…Taranabant, an orally active, potent, and highly selective CB‐1 receptor inverse agonist, is being developed for the treatment of obesity. This randomized,…”
Get full text

Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects by Wang, Ying-Hong, Schwartz, Jules I, Luo, Wen-Lin, Jumes, Patricia, Desai, Rajesh, Wenning, Larissa A, Wagner, John A, Lai, Eseng

“…Laropiprant is a selective antagonist of the prostaglandin D2 receptor subtype 1, and is primarily eliminated via glucuronidation with a minor contribution…”
Get more information

The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin by Schwartz, Jules I., Bugianesi, Kathleen J., Ebel, David L., De Smet, Marina, Haesen, Rita, Larson, Patrick J., Ko, Amy, Verbesselt, Rene, Hunt, Thomas L., Lins, Robert, Lens, Simone, Porras, Arturo G., Dieck, John, Keymeulen, Bart, Gertz, Barry J.

“…Objective The objective of this study was to examine the effect of 3 doses of rofecoxib (12.5, 25, and 50 mg) on the pharmacodynamics and pharmacokinetics of…”
Get full text

MK-0703 (a cyclooxygenase-2 inhibitor) in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study by Schwartz, Jules I, Kotey, Paul N-A, Fricke, Jr, James R, Gottesdiener, Keith

“…MK-0703 is a selective cyclooxygenase-2 inhibitor investigated for the treatment of acute pain and inflammation. The purpose of this single-dose, randomized,…”
Get full text